Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Company Overview

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $12.13 to $12.83
• 50-Day Range: $8.91 to $12.91
• 52-Week Range: $8.04 to $45.00
• Volume: 1.00 million shs
• Average Volume: 449,173 shs
• Market Capitalization: $342.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $53.50
• Consensus Rating: Buy

Arcturus Therapeutics Stock Analysis - MarketRank™

Arcturus Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 460th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Arcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arcturus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.22) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcturus Therapeutics is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcturus Therapeutics is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcturus Therapeutics has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.79% of the float of Arcturus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcturus Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcturus Therapeutics has recently increased by 5.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Arcturus Therapeutics does not currently pay a dividend.

Dividend Growth

Arcturus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.79% of the float of Arcturus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcturus Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcturus Therapeutics has recently increased by 5.25%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.57

News Sentiment

Arcturus Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.60% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARCT Stock Analysis - Frequently Asked Questions

How have ARCT shares performed this year?

Arcturus Therapeutics' stock was trading at $16.97 at the start of the year. Since then, ARCT stock has decreased by 26.1% and is now trading at $12.5410.
View the best growth stocks for 2025 here.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its earnings results on Monday, May, 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($1.58) by $1.06. The biotechnology company had revenue of $29.38 million for the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative trailing twelve-month return on equity of 22.39%.
Read the conference call transcript.

Who are Arcturus Therapeutics' major shareholders?

Top institutional investors of Arcturus Therapeutics include ARK Investment Management LLC (7.41%), Sumitomo Mitsui Trust Group Inc. (7.10%), Nikko Asset Management Americas Inc. (7.10%) and Vanguard Group Inc. (6.45%). Insiders that own company stock include Pad Chivukula, Magda Marquet and Keith C Kummerfeld.
View institutional ownership trends.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 5/30/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARCT
• CIK: 1410997
• Web: www.arcturusrx.com
• Phone: (858) 900-2660
• Fax: N/A
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $53.50
• High Stock Price Target: $70.00
• Low Stock Price Target: $32.00
• Potential Upside/Downside: +336.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.73 million
• Net Margins: -36.39%
• Pretax Margin: -38.15%
• Return on Equity: -22.39%
• Return on Assets: -14.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.76
• Quick Ratio: 4.76

Sales & Book Value

• Annual Sales: $131.27 million
• Price / Sales: 2.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.42 per share
• Price / Book: 1.18

Miscellaneous

• Outstanding Shares: 27,121,000
• Free Float: 22,943,000
• Market Cap: $332.39 million
• Optionable: Optionable
• Beta: 2.36